<DOC>
	<DOC>NCT03082209</DOC>
	<brief_summary>This is an open-label, Phase I, dose-escalation study to determine the determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously treated solid tumors or hematologic malignancies. The study will consist of 2 segments: Segment I (Dose Escalation) and Segment II (Dose Expansion).</brief_summary>
	<brief_title>A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Must have a diagnosis of a solid tumor, AML or nonHodgkin lymphoma (NHL) that has relapsed, progressed, or failed to respond after at least one systemic therapy. Must have measurable disease, as defined by RECIST 1.1, by computed tomography (CT) or magnetic resonance imaging (MRI), except those with AML, who must have histologically confirmed relapsed or refractory disease at the local institution. Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 2. Must have adequate hematologic, renal and hepatic function. Participants with history of brain metastases who have not shown clinical and radiographic stable disease for at least 28 days after definitive therapy. Receipt of any systemic anticancer agent, including investigational anticancer products, within 21 days prior to study drug administration or 5 halflives, whichever is longer. Participant with a history of cirrhosis or other indication of significant hepatic function compromise. Participant with a positive diagnosis of hepatitis A, B, or C.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>non-Hodgkin lymphoma</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>acute myeloid leukemia (AML)</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>colorectal cancer (CRC)</keyword>
</DOC>